IMMUPHARMA PLC — AGM Information 2021

Jun 28, 2021

National Storage Mechanism | Additional information

RNS Number : 3507D

Immupharma PLC

28 June 2021

GENERAL TEXT AMENDMENT

The following amendment has been made to the '2021 RESULT OF ANNUAL GENERAL MEETING' announcement released on 28/06/2021 at 11:03 a.m. under RNS No 3228D.

Update: As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,297 shares. (Previously read: 250,221,2975 shares).

All other details remain unchanged.

The full amended text is shown below.

28 June 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.

The results of each resolution were as follows:

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2020 together with the reports thereon of the directors and auditors of the Company	27,979,197	99.93	20,000	0.07	663,319
2. To re-appoint Dr Stephane Mery as a director of the Company	22,040,754	76.93	6,610,683	23.07	11,079
3. To re-appoint Nexia Smith & Williams as auditors of the Company	28,003,061	99.92	22,348	0.08	637,107
4. That the directors be authorised to allot shares on the basis set out in the Notice of Meeting	27,762,710	99.82	48,844	0.18	850,962
5. To waive pre-emption rights in respect of the issue of the shares on the basis set out in the Notice of Meeting	27,759,210	99.81	52,344	0.19	850,962

As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,297 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

End

For further information please contact:

ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman	+ 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge John Howes Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 3550 +44 (0) 203 815 8880 +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) Jean-Charles Snoy Degroof Petercam (Liquidity Provider) Erik De Clippel Backstage Communication Olivier Duquaine Gunther De Backer	+32 (0) 2 747 02 60 +32 (0) 2 287 95 34 +32 (0) 477 504 784 +32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFLLRTITFIL